Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03699618 · ClinicalTrials.gov registry record
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
A clinical trial, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- 1
- Enrollment target
NCT03699618: Clinical Trial study, sponsored by Johns Hopkins University.
NCT03699618 is a clinical trial that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03699618 was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).
Interventions
- DRUG Anti-VEGF
- OTHER Hemorrhage displacement + Anti-VEGF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-05-29 |
| Est. Completion | 2020-01-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03699618
The ClinicalTrials.gov registry entry for NCT03699618 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anti-VEGF is the first listed.
NCT03699618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03699618 about?
NCT03699618 is a clinical study titled "Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration". This study will define the limits of subretinal hemorrhage parameters that are consistent with a good visual outcome with aggressive anti-VEGF treatment in patients with neovascular age-related macular degeneration (NVAMD).
What is the current status of trial NCT03699618?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2019-05-29. Estimated completion is 2020-01-06.
What interventions are being tested in trial NCT03699618?
The interventions under investigation include: Anti-VEGF (DRUG), Hemorrhage displacement + Anti-VEGF (OTHER).
Who is sponsoring clinical trial NCT03699618?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.